Dear Editor {#sec1}
===========

We read with interest the recent meta-analysis by Shakiba *et al*. \[[@cit0001]\], which demonstrated that serum interleukin 6 (IL-6) levels are significantly higher in patients affected by hepatocellular carcinoma (HCC) compared to healthy controls and to patients with cirrhosis or chronic hepatitis. The authors conclude that IL-6 might play a pathogenetic role in hepatocarcinogenesis and that serum IL-6 may represent a potentially useful diagnostic biomarker. We agree with these conclusions, but we argue that a significant advance in understanding the relationship between serum IL-6 and HCC will require refining the analysis by taking into account factors that Shakiba *et al*. could not consider, the most important of which -- at least in our opinion -- is gender. In fact, HCC is characterized by a significant gender disparity, due to multiple mechanisms among which sex differences in MyD88-dependent IL-6 production have been considered paramount \[[@cit0002]\]. Experimental hepatocarcinogenesis data show that the administration of diethylnitrosamine (DEN) causes a larger increase in serum IL-6 in male mice than it does in female mice. Genetic ablation of IL-6 abolishes the gender differences in liver injury and the administration of estrogens to male DEN-treated mice decreases serum IL-6 concentration \[[@cit0002]\]. Estrogen-mediated inhibition of IL-6 production by Kupffer cells may thus protect females from developing liver cancer, especially among carriers of IL-6 polymorphisms associated with high production of IL-6 \[[@cit0003]\]. Consistent with this hypothesis are the results of a study conducted on patients with chronic hepatitis C, in which serum IL-6 levels predict development of HCC, but only among females, where they have a negative correlation with estradiol levels \[[@cit0004]\]. Nevertheless, others have observed that the association between high serum IL-6 concentrations and increased HCC risk depends on body mass index, and not gender \[[@cit0005]\].

In conclusion, while appreciating the attempt that Shakiba *et al*. made to give meta-analytical strength to the purported association between serum IL-6 and HCC, we wonder if further insight into this topic should not come from a re-analysis of the individual data of the studies they cite. This approach would allow them to take into account important modulating factors such as gender and body mass index.
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